XYLT1

Across TCGA pan-cancer cohorts, XYLT1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated XYLT1 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher XYLT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated XYLT1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

HNSC, LUAD, and GBM are the cancer types where XYLT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.485	0.878	<.001	28	view →
LUAD	OS	Median	All	0.590	0.829	.027	4	view →
GBM	DFS	Tertile	All	0.909	0.617	.009	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

XYLT1–HNSC (OS)

Open the HNSC breakdown →